共 13 条
[1]
Arber DA(2016)The2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia Blood 127 2391-2405
[2]
Vardiman JW(2009)The2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes Blood 114 937-951
[3]
Patnaik MM(2012)SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value Blood 119 569-572
[4]
Patnaik MM(2012)Prognostic irrelevance of ring sideroblast percentage in World Health Organization-defined myelodysplastic syndromes without excess blasts Blood 119 5674-5677
[5]
Bejar R(2011)Clinical effect of point mutations in myelodysplastic syndromes N. Engl. J. Med. 364 2496-2506
[6]
Papaemmanuil E(2011)Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts N. Engl. J. Med. 365 1384-1395
[7]
Patnaik MM(2017)Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T): 2017 update on diagnosis, risk-stratification, and management Am. J. Hematol. 92 297-310
[8]
Tefferi A(2016)Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia. Blood Cancer J. 6 1311-1317
[9]
Patnaik MM(2017)Targeted next-generation sequencing in myelodysplastic syndromes and prognostic interaction between mutations and IPSS-R Am. J. Hematol. 92 233-241
[10]
Tefferi A(2015)SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts Blood 126 3376-3382